SCHEMBL12879146

SCHEMBL12879146

CC[C@H]1O[C@@H](n2cnc(C(N)=O)n2)[C@H]2OC(C)(C)OC12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.54
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ ALDH1A1 P00352 3/20 0.54
▸ ADORA1 P30542 2/20 0.54
▸ TSHR P16473 2/20 0.54
▸ GLA P06280 1/20 0.54
▸ EIF4E P06730 1/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ TOP1 P11387 1/20 0.54
▸ THPO P40225 1/20 0.54
▸ PMP22 Q01453 1/20 0.54
▸ PNP P00491 3/20 0.40
▸ PI4KA P42356 1/20 0.40
▸ PI4K2B Q8TCG2 1/20 0.40
▸ PI4K2A Q9BTU6 1/20 0.40
▸ PI4KB Q9UBF8 1/20 0.40
▸ HTR2C P28335 1/20 0.39
▸ HTR2B P41595 1/20 0.39
▸ SLC6A3 Q01959 1/20 0.39
▸ TMEM97 Q5BJF2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7377274 0.91 LMNA (0.63) LMNASMN1; SMN2ALDH1A1ADORA1TSHR
SCHEMBL12879149 0.91 LMNA (0.63) LMNASMN1; SMN2ALDH1A1ADORA1TSHR
SCHEMBL3762066 0.91 LMNA (0.63) LMNASMN1; SMN2ALDH1A1ADORA1TSHR
SCHEMBL24024511 0.91 LMNA (0.54) LMNASMN1; SMN2ALDH1A1ADORA1TSHR
SCHEMBL6839692 0.91 LMNA (0.63) LMNASMN1; SMN2ALDH1A1ADORA1TSHR
SCHEMBL24024691 0.91 LMNA (0.63) LMNASMN1; SMN2ALDH1A1ADORA1TSHR
SCHEMBL13058163 0.91 LMNA (0.63) LMNASMN1; SMN2ALDH1A1ADORA1TSHR
SCHEMBL12892430 0.91 LMNA (0.63) LMNASMN1; SMN2ALDH1A1ADORA1TSHR
SCHEMBL6912406 0.86 LMNA (0.49) LMNASMN1; SMN2ALDH1A1ADORA1TSHR
SCHEMBL24024831 0.84 LMNA (0.47) LMNASMN1; SMN2ALDH1A1ADORA1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9149538-B2 Oligomer conjugates of heteropentacyclic nucleosides NEKTAR THERAPEUTICS (US) 2015-10-06 — — US disclosed
US-20140288295-A1 OLIGOMER CONJUGATES OF HETEROPENTACYCLIC NUCLEOSIDES NEKTAR THERAPEUTICS 2014-09-25 — — US disclosed
US-8778898-B2 Oligomer conjugates of heteropentacyclic nucleosides NEKTAR THERAPEUTICS (US) 2014-07-15 — — US disclosed
US-20130261072-A1 OLIGOMER CONJUGATES OF HETEROPENTACYCLIC NUCLEOSIDES NEKTAR THERAPEUTICS (US) 2013-10-03 — — US disclosed
US-8466276-B2 Oligomer conjugates of heteropentacyclic nucleosides NEKTAR THERAPEUTICS (US) 2013-06-18 — — US disclosed
US-20110039797-A1 Oligomer Conjugates of Heteropentacyclic Nucleosides Nektar Therapetics (US) 2011-02-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039797-A1 Oligomer Conjugates of Heteropentacyclic Nucleosides SLC29A2, SLC29A1, GNE LMNA 3873/4885SMN1; SMN2 2799/4885ALDH1A1 2313/4885
US-20140288295-A1 OLIGOMER CONJUGATES OF HETEROPENTACYCLIC NUCLEOSIDES SLC29A2, SLC29A1, GNE LMNA 3873/4885SMN1; SMN2 2799/4885ALDH1A1 2313/4885
US-20130261072-A1 OLIGOMER CONJUGATES OF HETEROPENTACYCLIC NUCLEOSIDES GNE, SLC29A2, ABCG2 LMNA 3345/4885SMN1; SMN2 2130/4885ALDH1A1 2749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback